Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer

被引：0
|
作者：
Y. F. Yu
Y. Wang
T. P. Fu
K. Chen
J. Q. Liu
H. R. Yao
机构：
[1] Sun Yat-sen Memorial Hospital,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center
[2] Sun Yat-sen University,Department of Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
[3] Sun Yat-sen University Cancer Center,Department of Oncology
[4] Sun Yat-sen Memorial Hospital,undefined
[5] Sun Yat-sen University,undefined
来源：
Breast Cancer Research and Treatment | 2018年 / 168卷
关键词：
Metastatic breast cancer; HER2-positive; Trastuzumab; Single-agent chemotherapy; Doublet-agent chemotherapy; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：337 / 348
页数：11
相关论文
共 50 条
  • [31] Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
    Eiermann, W
    ANNALS OF ONCOLOGY, 2001, 12 : 57 - 62
  • [32] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced HER2-positive breast cancer
    Ghosn, M.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    El-Mouhebb, M.
    Mourad, C.
    Farhat, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S183
  • [33] ORAL VINORELBINE IN COMBINATION WITH TRASTUZUMAB AS A FIRST LINE THERAPY OF METASTATIC OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER
    Farhat, Fadi
    Kattan, Joseph
    Ghosn, Marwan
    BREAST, 2015, 24 : S42 - S43
  • [34] Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
    Wilks, Sharon
    Puhalla, Shannon
    O'Shaughnessy, Joyce
    Schwartzberg, Lee
    Berrak, Erhan
    Song, James
    Cox, David
    Vandat, Linda
    CLINICAL BREAST CANCER, 2014, 14 (06) : 405 - 412
  • [35] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced Her2-positive breast cancer
    Farhat, F.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    Ghosn, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S281 - S281
  • [36] Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer
    Leung, John Hang
    Tai, Yun-sheng
    Wang, Shyh-Yau
    Fion, Hei-Tung Yip
    Tsung-chin, Ho
    Chan, Agnes Lf
    BREAST, 2022, 65 : 91 - 97
  • [37] Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    Prat, Aleix
    Rossi, Valentina
    Valabrega, Giorgio
    Sperinde, Jeff
    Peraldo-Neia, Caterina
    Donadio, Michela
    Galvan, Patricia
    Sapino, Anna
    Aglietta, Massimo
    Baselga, Jose
    Scaltriti, Maurizio
    MOLECULAR ONCOLOGY, 2014, 8 (01) : 20 - 26
  • [38] Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
    Montemurro, F.
    Prat, A.
    Rossi, V.
    Valabrega, G.
    Sperinde, J.
    Peraldo-Neia, C.
    Donadio, M.
    Galvan, P.
    Sapino, A.
    Aglietta, M.
    Baseiga, J.
    Scaltriti, M.
    CANCER RESEARCH, 2013, 73
  • [39] Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials
    Clavarezza, Matteo
    Puntoni, Matteo
    Gennari, Alessandra
    Paleari, Laura
    Provinciali, Nicoletta
    D'Amico, Mauro
    DeCensi, Andrea
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4594 - 4603
  • [40] Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer
    Kamal, A. H.
    Camacho, F.
    Anderson, R.
    Wei, W.
    Balkrishnan, R.
    Kimmick, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 371 - 378
12345